# An Extension Study to Evaluate the Long-Term Safety and Durability of Effect of LUM001 in the Treatment of Cholestatic Liver Disease in Pediatric Subjects With Alagille Syndrome

> **NCT02117713** · PHASE2 · COMPLETED · sponsor: **Mirum Pharmaceuticals, Inc.** · enrollment: 34 (actual)

## Conditions studied

- Alagille Syndrome

## Interventions

- **DRUG:** LUM001 (Maralixibat)

## Key facts

- **NCT ID:** NCT02117713
- **Lead sponsor:** Mirum Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-03-16
- **Primary completion:** 2020-06-01
- **Final completion:** 2020-06-01
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2021-07-01

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02117713

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02117713, "An Extension Study to Evaluate the Long-Term Safety and Durability of Effect of LUM001 in the Treatment of Cholestatic Liver Disease in Pediatric Subjects With Alagille Syndrome". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02117713. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*